Chief Executive Officer and Director
Robert Berman has served as our Chief Executive Officer since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of ITUS Corporation, a Nasdaq listed company that is developing a liquid biopsy technology for early cancer detection. Prior to ITUS, Mr. Berman was the CEO of VIZ Technologies, a start-up company which developed a beverage dispensing cap, and he was the founder of IP Dispute Resolution Corporation, a company focused on intellectual property licensing. From 2000 to March 2007 Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, which became the preeminent, publicly traded company for licensing and enforcing patented technologies. He started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northwestern University School of Law, where he is an adjunct faculty member.
Chief Financial Officer
Marc Glickman, M.D.
Senior Vice President and Chief Medical Officer
Marc H. Glickman, M.D. has served as our Senior Vice President and Chief Medical Officer since May 2016 and served as member of our board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case Western Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Austin, Texas.
Benedict Broennimann, M.D.
Chief Medical Officer, Outside of United States
Benedict Broennimann, M.D. has served as our Chief Medical Officer, Outside of United States, since April 2018. He was our Co-Chief Executive Officer from August 2017 to April 2018. From 2006 to 2008, Dr. Broennimann served as our Chairman and Chief Executive Officer, and from 2009 to 2015 he was engaged by us as a consultant to facilitate our efforts to gain various regulatory approvals in Europe. From 2004 to 2008, he was also Chief Executive Officer of Leman Cardiovascular S.A., where he spearheaded fundraising and cardiovascular device developments. Dr. Broennimann served as Principal at Heidrick & Struggles from 2000 to 2002 and Highland Partners from 2003 to 2004. He also served as a Senior Partner at Rosewall Ventures, Ltd. from 2008 to 2011. Dr. Broennimann attended the University of Bern in Switzerland, where he received his Doctor of Medicine, and was Chief Resident in the Department of General Surgery and Transplantation at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland. Dr. Broennimann is also board certified in general surgery and pharmaceutical medicine.
Vice President of Regulatory Affairs and Quality Assurance
Ms. Sarner has more than twenty-five years of experience working with a variety of medical device companies from start-ups to industry leaders, as well as six years as a medical device regulator. While in the private sector, Ms. Sarner has worked on 30 products that have received FDA approval and CE mark certification, and as a regulator she has reviewed and granted CE mark certification for more than 50 Class III medical devices. She comes to Hancock Jaffe from a senior position at DEKRA Certification B.V., a European Notified Body where she reviewed design dossiers and conducted quality systems and regulatory audits for medical device companies seeking CE marking. Her prior medical device industry experience includes regulatory strategy, quality assurance, new product development, project management, and clinical marketing in leadership positions at Arbor Surgical Technologies (sold to Medtronic), Edwards Lifesciences, Baxter Healthcare, and Medtronic, primarily on tissue based surgical and percutaneous cardiovascular implants. In her previous roles, Chris has led numerous new and innovative product development projects, including Transcatheter Aortic Valve Implant (TAVI) devices, Modular Aortic Valve devices, and Abdominal Aortic Aneurysm systems, from early feasibility to commercialization. Her technical expertise includes tissue engineering, microbiology, biochemistry, biocompatibility, microbiology and sterilization.
Ms. Sarner has an MBA from Pepperdine University Graziadio School of Business and Management, and a B.S. in Biological Science from the University of California, Irvine.